Arcus Biosciences, Inc. (RCUS) has a negative trailing P/E of -6.8, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 13.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -14.70%, forward earnings yield 7.52%.
Criteria proven by this page:
Overall SharesGrow Score: 55/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -23.2 | 0.00 | 4.20 | 0.00 | - |
| 2017 | -7.9 | -0.04 | 2.71 | 295.42 | - |
| 2018 | -7.5 | 0.22 | 1.59 | 44.64 | - |
| 2019 | -5.2 | -0.25 | 2.70 | 29.51 | - |
| 2020 | -11.6 | -0.50 | 2.83 | 18.23 | - |
| 2021 | 53.0 | -0.39 | 3.34 | 7.33 | - |
| 2022 | -5.6 | 0.01 | 2.27 | 13.29 | - |
| 2023 | -4.6 | -0.39 | 3.06 | 12.08 | - |
| 2024 | -4.7 | 0.19 | 2.77 | 5.20 | - |
| 2025 | -7.3 | -1.52 | 4.06 | 10.36 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-0.73 | $0.00 | $-17.97M | - |
| 2017 | $-1.25 | $1.41M | $-53.08M | -3756.7% |
| 2018 | $-1.43 | $8.35M | $-49.59M | -593.7% |
| 2019 | $-1.73 | $15M | $-75.93M | -506.2% |
| 2020 | $-2.13 | $77.52M | $-116.68M | -150.5% |
| 2021 | $0.71 | $382.88M | $53M | 13.8% |
| 2022 | $-3.71 | $112M | $-267M | -238.4% |
| 2023 | $-4.15 | $117M | $-307M | -262.4% |
| 2024 | $-3.14 | $258M | $-283M | -109.7% |
| 2025 | $-3.29 | $247M | $-353M | -142.9% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-3.81 | $-5.33 – $-2.31 | $92.28M | $52.63M – $233.45M | 6 |
| 2027 | $-3.34 | $-4.37 – $-2.09 | $111.64M | $22.69M – $204.2M | 6 |
| 2028 | $-2.19 | $-2.74 – $-1.38 | $195.65M | $187.1M – $204.2M | 8 |
| 2029 | $-0.77 | $-1.98 – $-0.04 | $453.91M | $122.55M – $998.68M | 6 |
| 2030 | $1.70 | $0.09 – $4.36 | $946.58M | $255.56M – $2.08B | 6 |
